Compare KEN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | ABCL |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Singapore | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2014 | 2020 |
| Metric | KEN | ABCL |
|---|---|---|
| Price | $62.95 | $12.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $16.82 |
| AVG Volume (30 Days) | 9.8K | ★ 4.7M |
| Earning Date | 12-02-2026 | 11-09-2026 |
| Dividend Yield | ★ 6.07% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.12 |
| P/E Ratio | $9.21 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $48.23 | $2.75 |
| 52 Week High | $95.93 | $14.98 |
| Indicator | KEN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 45.97 |
| Support Level | $58.89 | $11.78 |
| Resistance Level | $70.27 | $12.88 |
| Average True Range (ATR) | 1.26 | 0.75 |
| MACD | 0.34 | -0.26 |
| Stochastic Oscillator | 61.19 | 8.65 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include: OPC Power Plants, which generates and supplies electricity and energy in Israel; and CPV Group, which generates and supplies electricity and energy in the United States. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.